For Animal Use Only

Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents or preservatives. Discard unused portion. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1:

Lactated Ringer's Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis, depending on the clinical condition of the patient.

Lactated Ringer's Injection, USP produces a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to carbon dioxide and water, which requires consumption of hydrogen cations

Lactated Ringer's Injection, USP is indicated as a source of water and electrolytes or as an alkalinizing agent

None known. 

Do not administer to horses by intraperitoneal injection.

Lactated Ringer's Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

Lactated Ringer's Injection, USP should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

Lactated Ringer's Injection, USP should be used with great care, in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.

Lactated Ringer's Injection, USP should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation

The intravenous administration of Lactated Ringer's Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, over hydration, congested states, or pulmonary edema. The risk of dilutive states is inversely proportional to the electrolyte concentration of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

In patients with diminished renal function, administration of lactated Ringer's Injection, USP may result in sodium or potassium retention.

Lactated Ringer's Injection, USP is not used for treatment of lactic acidosis.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Lactated Ringer's Injection,USP must be used with caution. Excess administration may result in metabolic alkalosis.

Caution must be exercised in the administration of Lactated Ringer's Injection, USP to patients receiving corticosteroids or corticotrophin. 

Do not administer unless solution is clear and seal is intact.

As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

All solutions for injections in plastic containers are intended for intravenous administration using sterile equipment and aseptic technique.

Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. Discard unused portion.

In an event of over hydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See Warnings. Precautions and Adverse Events.

Veterinary Lactated Ringer's Injection, USP in plastic container is available as follows:

*PVC Free, DEHP Free and Latex Free Bag. The volumetric scales on the single dose plastic container should only be used as a reference. For precise dosage of volumes it is recommeded the use of IV Infusion pump or IV Burrette. 

**The plastic container is fabricated from a specially formulated polyvinyl chloride. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts withing the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in animals accourding to USP biological tests for plastic containers, as well as tissue culture toxicity studies.

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended that the product be stored in the moisture overwrap at room temperature (250C/770F); brief exposure  up to (400C/1040F) does not adversely affect the product.

To OpenTear overwrap down side at slit and remove solution container.  Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.  Check for minute leaks by squeezing inner bag firmly.  If leaks are found, discard solution as sterility may be impaired.  If supplemental medication is desired, follow directions below.

Preparation for Administration1.  Suspend container from eyelet support.

2.  Remove protector from outlet port at bottom of container.

3.  Attach administration set.  Refer to complete directions accompanying set.

To Add Medication
WARNING:  Additives may be incompatible.

To add medication before solution administration1.  Prepare medication site.

2.  Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.

3.  Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration1.  Close clamp on the set.

2.  Prepare medication site.

3.  Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.

4.  Remove container from IV pole and/or turn to an upright position.

5.  Evacuate both ports by squeezing them while container is in the upright position.

6.  Mix solution and medication thoroughly.

7.  Return container to in-use position and continue administration.

CAUTION:  Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.

Manufactured for:

IVALI LLC18205 Biscayne Blvd., Suite 2202
Aventura Florida

Printed in Argentina
For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call IVALI LLC. Customer service at 1-305-692-7665
IVALI is a trademark of IVALI LLC., all rights reserved.
© 2018 IVALI LLC.

NDC 86094-898-25
Veterinary Lactated Ringer's Injection, USP
250 ml

NDC 86094-898-50
Veterinary Lactated Ringer's Injection, USP
500 ml

86094-898-01
Veterinary Lactated Ringer's Injection, USP
1000 ml

86094-898-03
Veterinary Lactated Ringer's Injection, USP
3000 ml

NDC 50989-898-05

Veterinary Lactated Ringer's Injection, USP
5000 ml